Mixed Amphetamine Salts Most Effective In The Treatment Of ADHD in Youths Reports The SUNY Upstate Medical Center
Published: May 24, 2006
TORONTO, May 24 /PRNewswire/ -- Stimulant medications, such as mixed amphetamine salts (MAS) and methylphenidates are significantly more effective than nonstimulant ADHD medications or novel stimulants, such as modafinil, in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). This conclusion is based on a meta-analysis of 29 controlled-treatment studies representing the past 25 years of research involving nearly 4,500 children with ADHD presented today at the 2006 American Psychiatric Association meeting in Toronto, Canada.
Among stimulant medications classes, long-acting mixed amphetamine salts (MAS XR) and immediate-release mixed amphetamine salts showed a similar level of efficacy to short- or long-acting methylphenidates. The effectiveness of short- and long-acting stimulants did not differ from one another.
"The larger effect sizes we calculated for stimulant ADHD medications, compared to nonstimulants or the novel stimulant modafinil, leads us to conclude that amphetamine and methylphenidate based stimulant medications are more effective in treating symptoms of ADHD," said Stephen V. Faraone, Ph.D., lead researcher and director of child and adolescent psychiatry at SUNY Upstate Medical University. "Our results should help physicians who have had to rely on qualitative comparisons among published trials, along with their own clinical experience, to draw conclusions about an ADHD medication's relative efficacy because of largely absent direct head-to-head drug comparisons."
The researchers compared study outcomes using effect sizes, a commonly used, standard statistical measure to determine the magnitude of a particular effect resulting from an intervention, such as a drug used on a population, irrespective of the population size. Effect sizes are generally categorized as small (0.2), medium (0.5) and large (0.8). Standardized mean averages, or effect sizes, for dependent measures in each study were computed by taking the mean of the active drug group minus the mean of the placebo group and dividing the result by the pooled standard deviation of the groups.
After adjusting for the influence of individual study design features, the researchers calculated effect size based on Total ADHD scores. Long-acting and short-acting stimulant medications showed the largest effect size among all medications (E = 0.83 and E = 0.9 respectively), followed by nonstimulant or modafinil based stimulants medications (E = 0.62). Statistically significant differences in effect size occurred in comparisons between nonstimulant/modafinil based stimulant medications and long-acting (p = 0.004) as well as short-acting stimulants (p = 0.002).
For the analysis, Faraone and his colleagues used data from 29 double-blind, placebo-controlled treatment studies of 4,465 children with ADHD, with an average age 10 years, published during or after 1980. Designs for all of the studies were randomized, double-blind with placebo controls that lasted for two or more weeks in populations diagnosed with ADHD as defined using criteria from the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition or Fourth Edition (DSM).
The analysis included 15 drugs using 17 different outcome measures of ADHD symptoms, including hyperactive, inattentive, impulsive or oppositional behavior. The most commonly identified treatments included both methylphenidate and amphetamine compounds. Nonstimulant drugs included in the analysis were atomoxetine, bupropion, modafinil and desipramine.
Shire US Inc. supported the study.
ADHD is a neurological brain disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than typically observed in individuals at a comparable age and maturity level. Because everyone shows signs of these behaviors at times, the behaviors must appear early in life (before age 7 years) and continue for at least six months, according to the ADHD diagnosis criteria as defined in DSM-IV-TR(R). Up to 65 percent of children with ADHD may still exhibit symptoms into adulthood. In fact, approximately eight million American adults currently struggle with the inattention, impulsivity and hyperactivity symptoms of ADHD.
Without an effective treatment program, the symptoms of ADHD may lead to potentially serious consequences. A survey has shown that when compared to adults without ADHD symptoms, adults with untreated ADHD were more than twice as likely to have been arrested, 47 percent more likely to have received more than one speeding ticket in the last year, twice as likely to have been divorced and twice as likely to have held six or more jobs in the past decade.
Further, evidence suggests that many adults with untreated ADHD may be at risk for other problems, including poor performance in the workplace and poor self-image. Although there is no cure for ADHD, physicians and advocates are finding ways to help people with the condition learn to adapt to their school, home, social and work settings. ADHD usually can be successfully managed with behavioral therapy, structured coping techniques and medication. Psychostimulant medications are thought to stimulate areas of the brain that control attention, impulses, and self-regulation of behavior, remain among the most successful treatments for people with ADHD. Up to 70 percent of children with ADHD respond positively to psychostimulants. Medication should be considered part of an overall multi-modal treatment plan for ADHD.
About SUNY Upstate Medical University
SUNY Upstate Medical University, located in Syracuse, N.Y., is a comprehensive academic medical center featuring an aggressive program of biomedical research with world experts in the areas of ADHD, neural coding, heart arrhythmias, enzyme structure and function and human retro viruses. In addition to its research program, the university features the colleges of Graduate Studies, Health Profession, Medicine and Nursing, and a teaching hospital, University Hospital that sees more than 130,000 patient visits annually.
Poster # NR 652: Comparing the Efficacy of Medications for ADHD Using Meta-Analysis. Stephen V. Faraone, Ph.D.SUNY Upstate Medical Center
CONTACT: Darryl Geddes of SUNY Upstate Medical Center, +1-315-464-4828; orPriya Namjoshi, +1-212-601-8337, +1-609-213-8987 on-site, or Marion Glick,+1-212-601-8273 or on site: +1-917-301-4206, both of Porter Novelli forShire